PT2560631E - Terapia à base de baclofeno e acamprosato de distúrbios neurológicos - Google Patents

Terapia à base de baclofeno e acamprosato de distúrbios neurológicos Download PDF

Info

Publication number: PT2560631E
Authority: PT; Portugal
Prior art keywords: baclofen; based therapy; neurogical; disorders; acamprosate
Prior art date: 2011-03-01

Application number

PT127081131T

Other languages

English (en)

Inventor

Ilya Chumakov

Daniel Cohen

Serguei Nabirochkin

Emmanuel Vial

Mickael Guedj

Original Assignee

Pharnext

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-03-01

Filing date

2012-03-01

Publication date

2014-02-24

2012-03-01 Application filed by Pharnext filed Critical Pharnext

2014-02-24 Publication of PT2560631E publication Critical patent/PT2560631E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Psychology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT127081131T 2011-03-01 2012-03-01 Terapia à base de baclofeno e acamprosato de distúrbios neurológicos PT2560631E (pt)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date
EP11305217		2011-03-01
US201161468658P	2011-03-29	2011-03-29
US201161493606P	2011-06-06	2011-06-06
EP11305687		2011-06-06

Publications (1)

Publication Number	Publication Date
PT2560631E true PT2560631E (pt)	2014-02-24

Family

ID=46758335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT127081131T PT2560631E (pt)	2011-03-01	2012-03-01	Terapia à base de baclofeno e acamprosato de distúrbios neurológicos

Country Status (26)

Country	Link
US (7)	US9820978B2 (pt)
EP (5)	EP2560631B1 (pt)
JP (2)	JP5987008B2 (pt)
KR (2)	KR101918745B1 (pt)
CN (2)	CN103596562B (pt)
AU (2)	AU2012222351B2 (pt)
BR (1)	BR112013022112B1 (pt)
CA (1)	CA2828765C (pt)
CY (3)	CY1115074T1 (pt)
DK (3)	DK2796132T3 (pt)
EA (2)	EA023277B1 (pt)
ES (5)	ES2665569T3 (pt)
HR (1)	HRP20140131T1 (pt)
HU (1)	HUE038653T2 (pt)
IL (2)	IL228177B (pt)
LT (2)	LT2796132T (pt)
MX (2)	MX340568B (pt)
PL (3)	PL2796132T3 (pt)
PT (1)	PT2560631E (pt)
RS (3)	RS57426B1 (pt)
SG (2)	SG192968A1 (pt)
SI (3)	SI2560631T1 (pt)
SM (3)	SMT201800327T1 (pt)
TR (1)	TR201809351T4 (pt)
WO (2)	WO2012117076A2 (pt)
ZA (1)	ZA201306039B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2065038A1 (en)	2007-11-30	2009-06-03	Pharnext	New therapeutic approaches for treating Charcot-Marie-Tooth disease
EP2135607A1 (en)	2008-06-18	2009-12-23	Pharnext	Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
US9393241B2 (en)	2009-06-02	2016-07-19	Pharnext	Compositions for treating CMT and related disorders
EP2263665A1 (en)	2009-06-02	2010-12-22	Pharnext	New compositions for treating CMT and related disorders
EP2322163A1 (en)	2009-11-03	2011-05-18	Pharnext	New therapeutics approaches for treating alzheimer disease
US9387206B2 (en)	2009-11-03	2016-07-12	Pharnext	Therapeutic approaches for treating Alzheimer's disease
CN108057033A (zh) *	2011-03-01	2018-05-22	法耐斯特公司	用于治疗肌萎缩性侧索硬化症的新组合物
US10010515B2 (en)	2011-03-01	2018-07-03	Pharnext	Therapeutic approaches for treating Parkinson's disease
UA113165C2 (xx) *	2011-03-01	2016-12-26		Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
EP2705842A1 (en) *	2012-09-05	2014-03-12	Pharnext	Therapeutic approaches for treating parkinson's disease
US9867837B2 (en) *	2011-03-01	2018-01-16	Pharnext	Compositions for treating neurological disorders
US9248111B2 (en)	2011-03-01	2016-02-02	Pharnext	Therapeutic approaches for treating parkinson's disease
US9241933B2 (en)	2011-03-01	2016-01-26	Pharnext	Compositions for treating amyotrophic lateral sclerosis
PT2560631E (pt)	2011-03-01	2014-02-24	Pharnext	Terapia à base de baclofeno e acamprosato de distúrbios neurológicos
US9931326B2 (en)	2011-03-29	2018-04-03	Pharnext	Composition comprising torasemide and baclofen for treating neurological disorders
GB2501457A (en)	2012-02-10	2013-10-30	Rational Intellectual Holdings Ltd	Assigning player positions in an online table game
AU2013224959B2 (en) *	2012-03-01	2017-12-07	Pharnext	New compositions for treating amyotrophic lateral sclerosis
JP6158234B2 (ja) *	2012-03-01	2017-07-05	ファーネクストＰｈａｒｎｅｘｔ	筋萎縮性側索硬化症の治療のための新規組成物
AU2013291970B2 (en) *	2012-07-18	2017-09-28	Pharnext	Baclofen and acamprosate based therapy of Macular Degeneration disorders
EP2705841A1 (en) *	2012-09-05	2014-03-12	Pharnext	Combinations of nootropic agents for treating cognitive dysfunctions
GB201300684D0 (en)	2013-01-15	2013-02-27	Apitope Int Nv	Peptide
CA2913331C (en)	2013-06-05	2021-08-24	Pharnext	Stable oral solutions for combined api
SG11201510451RA (en)	2013-06-19	2016-01-28	Som Innovation Biotech S L	Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders
KR102206745B1 (ko) *	2013-07-12	2021-02-03	경상대학교산학협력단	안토시아닌 및 gabab 수용체 작용제를 유효성분으로 포함하는 신경질환 치료제
WO2015023830A1 (en)	2013-08-14	2015-02-19	Stc.Unm	Treatment and prevention of stroke and other neurological disorders
EP3062782A1 (en) *	2013-10-30	2016-09-07	Pharnext	Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
KR20160111013A (ko)	2014-02-11	2016-09-23	파넥스트	신경질환의 치료를 위한 바클로펜, 아캄프로세이트 및 중쇄 트리-글리세리드의 조합
CA2967662A1 (en) *	2014-11-21	2016-05-26	Biohaven Pharmaceutical Holding Company Ltd.	Sublingual formulation of riluzole
IL255343B2 (en)	2015-05-04	2024-10-01	Confluence Pharmaceuticals Llc	Sprinkle formulations of acamprosate
EP3156050A1 (en) *	2015-10-16	2017-04-19	Universitat Autònoma De Barcelona	New combination therapies for treating neurological damage
WO2017115873A1 (ja)	2015-12-29	2017-07-06	国立大学法人京都大学	アルツハイマー病の予防及び／又は治療剤
WO2017134280A1 (en) *	2016-02-05	2017-08-10	Pharnext	Novel combinatorial therapies of neurological disorders
US10383870B2 (en)	2016-06-10	2019-08-20	Pharnext	Early treatment of CMT disease
EP3615017A1 (en) *	2017-04-24	2020-03-04	Pharnext	Idalopirdine-based combinatorial therapies of alzheimer's disease
US12042566B2 (en)	2017-05-17	2024-07-23	Confluence Pharmaceuticals, Llc	Formulations of homotaurines and salts thereof
AU2018310882C1 (en)	2017-07-31	2021-12-09	Novartis Ag	Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
KR20200035035A (ko)	2017-07-31	2020-04-01	노파르티스 아게	코카인 사용 감소 또는 코카인 사용 재발 예방에 있어서 마보글루란트의 용도
AU2019211135A1 (en) *	2018-01-29	2020-08-06	Pharnext	Baclofen and acamprosate based therapy of alzheimer's disease in patients having lost responsiveness to acetylcholinesterase inhibitor therapy
CN116059192B (zh)	2019-11-13	2024-10-29	润佳（苏州）医药科技有限公司	同位素富集的3-氨基-1-丙磺酸及其衍生物的用途
US20250134902A1 (en) *	2022-02-09	2025-05-01	Univesrity Of North Texas Health Science Center	Drug repurposing for delayed treatment of ischemic stroke
CN115350172A (zh) *	2022-08-12	2022-11-18	昆明医科大学	Gabapentin对AD情景记忆改善的应用
WO2025095099A1 (ja) *	2023-11-02	2025-05-08	株式会社ケイファーマ	前頭側頭葉変性症治療剤及び治療用組成物

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5721263A (en)	1993-06-07	1998-02-24	Takeda Chemical Industries, Ltd.	Pharmaceutical composition for angiotensin II-mediated diseases
US6573251B2 (en)	1994-03-30	2003-06-03	Denis Barritault	Drug and pharmaceutical composition for the treatment of lesions of the nervous system and fractions enriched in heparan sulfate
US6391922B1 (en) *	1998-01-13	2002-05-21	Synchroneuron, Llc	Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
AU3173301A (en)	2000-02-11	2001-08-20	European Molecular Biology Laboratory	Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
EP1406660B1 (en)	2001-07-19	2007-06-06	Pharmacia Corporation	Combination of an aldosterone receptor antagonist and an hmg coa reductase inhibitor
EP1485082A4 (en)	2002-02-19	2009-12-30	Xenoport Inc	PROCESS FOR THE SYNTHESIS OF PROMEDICAMENTS FROM 1-ACYL-ALKYL DERIVATIVES AND CORRESPONDING COMPOSITIONS
PL373032A1 (en)	2002-03-18	2005-08-08	Pharmacia Corporation	Combination of an aldosterone receptor antagonist and nicotinic acid or a nicotinic acid derivative
US20040102525A1 (en) *	2002-05-22	2004-05-27	Kozachuk Walter E.	Compositions and methods of treating neurological disease and providing neuroprotection
DK2465537T3 (en)	2002-10-10	2016-09-19	Ono Pharmaceutical Co	MICROSPHERE INCLUDING ONO-1301
MXPA06001876A (es)	2003-08-20	2006-05-17	Xenoport Inc	Prodrogas de aciloxialquil carbamato, metodos de sintesis y uso.
US7227028B2 (en)	2003-12-30	2007-06-05	Xenoport, Inc.	Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
JP4855268B2 (ja)	2004-11-30	2012-01-18	アンジェスＭｇ株式会社	アルツハイマー治療剤
US20080188510A1 (en)	2005-05-23	2008-08-07	Eisai R & D Management Co., Ltd.	Novel methods using zonisamide
JP2009513672A (ja)	2005-10-31	2009-04-02	ブレインセルス，インコーポレイティド	神経発生のｇａｂａ受容体媒介調節
WO2008006070A2 (en)	2006-07-06	2008-01-10	Roskamp Research Llc	Compounds and combinations thereof for inhibiting beta-amyloid production and methods of use thereof
ATE511392T1 (de)	2007-01-11	2011-06-15	Xenoport Inc	Verzögert freigesetzte orale dosierungsformen eines prodrugs von r-baclofen und behandlungsverfahren damit
ES2545959T3 (es)	2007-05-22	2015-09-17	Otsuka Pharmaceutical Co., Ltd.	Un medicamento consistente en un derivado de carboestirilo y donepezilo para el tratamiento de la enfermedad de Alzheimer
US20090082464A1 (en)	2007-09-07	2009-03-26	Bernd Jandeleit	Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090069419A1 (en)	2007-09-07	2009-03-12	Bernd Jandeleit	Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
TW200932734A (en)	2007-10-15	2009-08-01	Xenoport Inc	Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
US20090118365A1 (en) *	2007-11-06	2009-05-07	Xenoport, Inc	Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain
WO2009096985A1 (en)	2008-02-01	2009-08-06	Xenoport, Inc.	Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment
US20100137442A2 (en)	2008-02-01	2010-06-03	Xenoport, Inc.	Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment
DK2282779T3 (da)	2008-04-29	2013-05-27	Pharnext	Nye terapeutiske fremgangsmåder til behandling af alzheimer sygdom og beslægtede lidelser gennem en modulation af cellestress-respons
HRP20170531T1 (hr) *	2008-04-29	2017-06-16	Pharnext	Novi terapijski pristupi za liječenje alzheimerove bolesti i povezanih poremećaja putem modulacije angiogeneze
ES2764480T3 (es) *	2008-04-29	2020-06-03	Impact Coatings Ab	Composiciones de combinación para tratar la enfermedad de Alzheimer y trastornos relacionados con zonisamida y acamprosato
EP2135607A1 (en)	2008-06-18	2009-12-23	Pharnext	Combination of pilocarpin and methimazol for treating Charcot-MarieTooth disease and related disorders
RU2489433C9 (ru)	2008-11-27	2014-06-10	Нэшнл Юниверсити Корпорейшн Кагава Юниверсити	Производное циклобутилпурина, агент, активирующий ангиогенез, агент, активирующий образование просвета, агент, активирующий рост нейронов, и лекарственное средство
CN102300463B (zh) *	2008-12-04	2015-03-25	英特药业有限公司	扎来普隆(zaleplon)胃滞留药物传递系统
CN102341099A (zh)	2009-03-03	2012-02-01	什诺波特有限公司	R-巴氯芬前药的持续释放口服剂型
JP2012524065A (ja)	2009-04-17	2012-10-11	ゼノポート，インコーポレーテッド	ＧＡＢＡＢ受容体リガンドとしてのγ−アミノ酪酸誘導体
EP2263665A1 (en)	2009-06-02	2010-12-22	Pharnext	New compositions for treating CMT and related disorders
US9393241B2 (en)	2009-06-02	2016-07-19	Pharnext	Compositions for treating CMT and related disorders
US9387206B2 (en)	2009-11-03	2016-07-12	Pharnext	Therapeutic approaches for treating Alzheimer's disease
EP2322163A1 (en)	2009-11-03	2011-05-18	Pharnext	New therapeutics approaches for treating alzheimer disease
US9867837B2 (en)	2011-03-01	2018-01-16	Pharnext	Compositions for treating neurological disorders
US9241933B2 (en)	2011-03-01	2016-01-26	Pharnext	Compositions for treating amyotrophic lateral sclerosis
US10010515B2 (en)	2011-03-01	2018-07-03	Pharnext	Therapeutic approaches for treating Parkinson's disease
US9248111B2 (en)	2011-03-01	2016-02-02	Pharnext	Therapeutic approaches for treating parkinson's disease
PT2560631E (pt)	2011-03-01	2014-02-24	Pharnext	Terapia à base de baclofeno e acamprosato de distúrbios neurológicos
UA113165C2 (xx)	2011-03-01	2016-12-26		Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
US9931326B2 (en)	2011-03-29	2018-04-03	Pharnext	Composition comprising torasemide and baclofen for treating neurological disorders

2012
- 2012-03-01 PT PT127081131T patent/PT2560631E/pt unknown
- 2012-03-01 ES ES12706270.1T patent/ES2665569T3/es active Active
- 2012-03-01 ES ES13196468.6T patent/ES2678794T3/es active Active
- 2012-03-01 EP EP12708113.1A patent/EP2560631B1/en active Active
- 2012-03-01 MX MX2013010043A patent/MX340568B/es active IP Right Grant
- 2012-03-01 CA CA2828765A patent/CA2828765C/en active Active
- 2012-03-01 PL PL13196468T patent/PL2796132T3/pl unknown
- 2012-03-01 AU AU2012222351A patent/AU2012222351B2/en not_active Ceased
- 2012-03-01 SG SG2013064811A patent/SG192968A1/en unknown
- 2012-03-01 LT LTEP13196468.6T patent/LT2796132T/lt unknown
- 2012-03-01 WO PCT/EP2012/053570 patent/WO2012117076A2/en not_active Ceased
- 2012-03-01 WO PCT/EP2012/053568 patent/WO2012117075A2/en not_active Ceased
- 2012-03-01 SI SI201230019T patent/SI2560631T1/sl unknown
- 2012-03-01 US US14/002,429 patent/US9820978B2/en not_active Expired - Fee Related
- 2012-03-01 PL PL12708113T patent/PL2560631T3/pl unknown
- 2012-03-01 PL PL13196461T patent/PL2727588T3/pl unknown
- 2012-03-01 LT LTEP13196461.1T patent/LT2727588T/lt unknown
- 2012-03-01 ES ES13196461T patent/ES2698927T3/es active Active
- 2012-03-01 SI SI201231317T patent/SI2796132T1/sl unknown
- 2012-03-01 DK DK13196468.6T patent/DK2796132T3/en active
- 2012-03-01 EP EP13196461.1A patent/EP2727588B1/en active Active
- 2012-03-01 SI SI201231471T patent/SI2727588T1/sl unknown
- 2012-03-01 SM SM20180327T patent/SMT201800327T1/it unknown
- 2012-03-01 TR TR2018/09351T patent/TR201809351T4/tr unknown
- 2012-03-01 RS RS20180734A patent/RS57426B1/sr unknown
- 2012-03-01 HR HRP20140131AT patent/HRP20140131T1/hr unknown
- 2012-03-01 CN CN201280017651.0A patent/CN103596562B/zh not_active Expired - Fee Related
- 2012-03-01 EP EP12706270.1A patent/EP2680835B1/en not_active Not-in-force
- 2012-03-01 EP EP13196468.6A patent/EP2796132B1/en active Active
- 2012-03-01 SM SM20180618T patent/SMT201800618T1/it unknown
- 2012-03-01 EP EP18154734.0A patent/EP3332781A1/en not_active Withdrawn
- 2012-03-01 EA EA201300974A patent/EA023277B1/ru unknown
- 2012-03-01 KR KR1020137026027A patent/KR101918745B1/ko not_active Expired - Fee Related
- 2012-03-01 HU HUE13196468A patent/HUE038653T2/hu unknown
- 2012-03-01 BR BR112013022112-7A patent/BR112013022112B1/pt not_active IP Right Cessation
- 2012-03-01 RS RS20181431A patent/RS58114B1/sr unknown
- 2012-03-01 RS RS20140089A patent/RS53227B/sr unknown
- 2012-03-01 DK DK13196461.1T patent/DK2727588T3/en active
- 2012-03-01 ES ES12708113.1T patent/ES2450074T3/es active Active
- 2012-03-01 DK DK12708113.1T patent/DK2560631T3/da active
- 2012-03-01 KR KR1020187010681A patent/KR101937782B1/ko not_active Expired - Fee Related
- 2012-03-01 JP JP2013555881A patent/JP5987008B2/ja not_active Expired - Fee Related
- 2012-03-01 MX MX2016009146A patent/MX373746B/es unknown
- 2012-03-01 CN CN201610286391.7A patent/CN105997969B/zh not_active Expired - Fee Related
- 2012-12-03 US US13/691,981 patent/US8865769B2/en active Active
- 2012-12-06 US US13/706,907 patent/US8741886B2/en active Active
2013
- 2013-02-28 EA EA201891833A patent/EA201891833A1/ru unknown
- 2013-02-28 ES ES18157222T patent/ES2845204T3/es active Active
- 2013-02-28 SG SG10201610587SA patent/SG10201610587SA/en unknown
- 2013-08-12 ZA ZA2013/06039A patent/ZA201306039B/en unknown
- 2013-08-29 IL IL228177A patent/IL228177B/en active IP Right Grant
2014
- 2014-02-27 CY CY20141100159T patent/CY1115074T1/el unknown
- 2014-03-12 SM SM201400029T patent/SMT201400029B/xx unknown
- 2014-09-08 US US14/479,614 patent/US9144558B2/en active Active
2015
- 2015-09-22 US US14/861,169 patent/US9636316B2/en not_active Expired - Fee Related
2017
- 2017-04-24 US US15/494,732 patent/US20170231958A1/en not_active Abandoned
- 2017-06-07 JP JP2017112687A patent/JP6416328B2/ja not_active Expired - Fee Related
- 2017-07-31 AU AU2017210501A patent/AU2017210501B2/en not_active Ceased
2018
- 2018-06-27 CY CY20181100664T patent/CY1120369T1/el unknown
- 2018-09-12 IL IL261725A patent/IL261725A/en unknown
- 2018-11-28 CY CY181101262T patent/CY1120925T1/el unknown
2019
- 2019-11-25 US US16/694,231 patent/US20200085790A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP2796132A1 (en)	2014-10-29
SI2560631T1 (sl)	2014-06-30
SG192968A1 (en)	2013-09-30
EP3332781A1 (en)	2018-06-13
RS58114B1 (sr)	2019-02-28
EP2796132B1 (en)	2018-05-02
KR20180043844A (ko)	2018-04-30
CY1120369T1 (el)	2019-07-10
EP2727588A1 (en)	2014-05-07
SMT201800618T1 (it)	2019-02-28
BR112013022112B1 (pt)	2021-09-28
CA2828765C (en)	2019-07-30
AU2012222351B2 (en)	2017-05-18
SI2796132T1 (sl)	2018-09-28
ES2665569T3 (es)	2018-04-26
JP6416328B2 (ja)	2018-10-31
US8865769B2 (en)	2014-10-21
WO2012117076A2 (en)	2012-09-07
EP2680835A2 (en)	2014-01-08
JP5987008B2 (ja)	2016-09-06
US20130090307A1 (en)	2013-04-11
ES2845204T3 (es)	2021-07-26
DK2727588T3 (en)	2018-12-10
KR20140038378A (ko)	2014-03-28
ES2678794T3 (es)	2018-08-17
CY1120925T1 (el)	2019-12-11
US8741886B2 (en)	2014-06-03
US20140378440A1 (en)	2014-12-25
CY1115074T1 (el)	2016-12-14
ES2698927T3 (es)	2019-02-06
US9636316B2 (en)	2017-05-02
US20140080873A1 (en)	2014-03-20
PL2727588T3 (pl)	2019-04-30
US9144558B2 (en)	2015-09-29
SMT201800327T1 (it)	2018-09-13
KR101918745B1 (ko)	2018-11-15
AU2017210501A1 (en)	2017-08-17
ZA201306039B (en)	2014-10-29
MX340568B (es)	2016-07-14
LT2796132T (lt)	2018-10-10
US20200085790A1 (en)	2020-03-19
RS53227B (sr)	2014-08-29
HK1203158A1 (en)	2015-10-23
AU2017210501B2 (en)	2018-11-01
EP2560631B1 (en)	2014-01-15
EP2727588B1 (en)	2018-08-29
HK1182615A1 (en)	2013-12-06
US20170231958A1 (en)	2017-08-17
LT2727588T (lt)	2019-01-25
EA201891833A1 (ru)	2019-01-31
NZ614184A (en)	2015-08-28
WO2012117076A3 (en)	2012-10-26
WO2012117075A3 (en)	2012-12-13
WO2012117075A2 (en)	2012-09-07
JP2017193562A (ja)	2017-10-26
HRP20140131T1 (hr)	2014-05-09
US9820978B2 (en)	2017-11-21
TR201809351T4 (tr)	2018-07-23
CA2828765A1 (en)	2012-09-07
EA023277B1 (ru)	2016-05-31
US20130085122A1 (en)	2013-04-04
DK2796132T3 (en)	2018-07-23
JP2014510069A (ja)	2014-04-24
IL228177B (en)	2018-01-31
BR112013022112A2 (pt)	2018-06-26
PL2560631T3 (pl)	2014-06-30
ES2450074T3 (es)	2014-03-21
PL2796132T3 (pl)	2018-10-31
SI2727588T1 (sl)	2019-03-29
EP2680835B1 (en)	2018-02-07
HUE038653T2 (hu)	2018-11-28
CN103596562B (zh)	2016-06-01
CN105997969B (zh)	2022-03-25
RS57426B1 (sr)	2018-09-28
US20160000736A1 (en)	2016-01-07
CN105997969A (zh)	2016-10-12
MX2013010043A (es)	2014-02-11
CN103596562A (zh)	2014-02-19
AU2012222351A1 (en)	2013-08-29
SG10201610587SA (en)	2017-02-27
IL261725A (en)	2018-10-31
EP2560631A2 (en)	2013-02-27
EA201300974A1 (ru)	2014-01-30
SMT201400029B (it)	2014-07-07
KR101937782B1 (ko)	2019-01-11
DK2560631T3 (da)	2014-02-10
MX373746B (es)	2020-05-20

Publication	Publication Date	Title
ZA201306039B (en)	2014-10-29	Baclofen and acamprosate based therapy of neurogical disorders
IL274469A (en)	2020-06-30	Compositions, uses and methods for the treatment of metabolic disorders and diseases
IL269852B (en)	2021-08-31	Combined treatments and uses for the treatment of demyelination disorders
EP2925775A4 (en)	2016-07-13	COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLISM DISEASES AND DRESSINGS
ZA201205829B (en)	2013-05-29	Treatment of respiratory disorders
ZA201301601B (en)	2018-12-19	Treatment of diseases
IL225896A0 (en)	2013-06-27	Treatment of mecp-2 related disorders
EP2709632A4 (en)	2015-03-04	COMPOSITIONS AND METHOD FOR THE TREATMENT OF SKIN DISEASES
ZA201500663B (en)	2016-10-26	Baclofen and acamprosate based therapy of macular degeneration disorders
PT2694049T (pt)	2019-02-06	Tapentadol para prevenir a cronicidade da dor
GB201114289D0 (en)	2011-10-05	Flurbiprofen and related compounds for the treatment of skin diseases
GB201107467D0 (en)	2011-06-15	Novel treatment of pain
IL256992B (en)	2020-09-30	Baclofen and acamprosate based therapy of neurogical disorders
GB201001912D0 (en)	2010-03-24	Treatment of respiratory disorders
AU2011902407A0 (en)	2011-07-07	Treatment of pain
HK1189155A (en)	2014-05-30	Treatment of mecp2-associated disorders